This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.
This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.

People aged 65+

Updated on 15/03/2018

DIABETES
An over 65 year old diabetes patient enjoying their new phase of life

What is different about people over 65 years old?

Turning 65 years old means a changing future and new opportunities.1

But for people with diabetes, turning 65 can also mean increasing concerns about their condition.1,2 People with diabetes aged 65 years or older face high rates of renal impairment,3 higher CV risk,4,5 and higher risk of emergency department visits due to hypoglycaemia.6

Choosing an appropriate diabetes treatment can be challenging.

An over-65 year old patient diabetes enjoying their new phase of life

JANUVIA is not licensed for anyone <18 years old.7

JANUVIA can meet the needs of people over 65 years old with T2DM

JANUVIA can help you support people as they begin a new phase of their lives, offering proven efficacy at reducing HbA1c8 and established safety9 within this age group.

JANUVIA effectively reduces blood glucose8

Helping your people over 65 years old to gain better control of their blood glucose is a priority of diabetes treatment.10

In people over 65 years old, JANUVIA has been shown to effectively reduce HbA1c, with a mean 0.5% reduction from baseline,8 in line with NICE recommendations for best practice.10

Change in HbA1c over 24 weeks8

Graph showing mean change in HbA1c for people aged 65 or over using JANUVIA compared with placebo

Adapted from Barzilai N et al. 20118
*p<0.001 for between-group comparisons of LS-mean at timepoints for which inference testing was prespecified

Study design

JANUVIA has an established safety profile for your 65+ patients9,11,12

Many of your older patients may experience renal damage that can lead to increased cardiovascular risk.3

The Trial Evaluating Cardiovascular Outcomes With Sitagliptin (TECOS) found that, when added to usual care in people ≥65 years old, JANUVIA demonstrated:

No increased
cardiovascular risk9


Primary composite cardiovascular outcome was cardiovascular death, nonfatal stroke, nonfatal myocardial infarction, or hospitalisation for unstable angina.9

No increased risk of hospitalisation for heart
failure* included in
TECOS sub-analysis9,11


*Hospitalisation for heart failure was a secondary endpoint in the TECOS study9,11

JANUVIA had no adverse effect on kidney outcomes, regardless of baseline eGFR in TECOS12

The CV safety profile for JANUVIA was demonstrated in TECOS9

The Trial Evaluating Cardiovascular Outcomes With Sitagliptin (TECOS) explored the safety of JANUVIA in the longest CV safety trial of DPP-4 inhibitors in type 2 diabetes to date vs usual care alone.9

Randomised double blind CV safety trial9

Over 14,000 patients9

3 years median follow up9

Study design

JANUVIA offers low risk of hypoglycaemia across a range of HbA1c levels13

In people aged 65 and over, the risk of daytime and night-time hypoglycaemia can be an increasing concern, in some cases restricting activities such as driving.1 With JANUVIA, they can maintain the same low risk of hypoglycaemia as in younger patients with T2DM.13

Risk of hypoglycaemia by attained HbA1c level

Graph showing risk of hypoglycaemia vs HbA1c level for T2DM populations aged over or under 65 years old, using either glipizide plus metformin or JANUVIA plus metformin

Adapted from Krobot et al, 2012

Study design

Related content

 

References

  1. Quandt SA et al. J Appl Gerontol. 2013;32(7):783–803.
  2. Gorawara-Bhat R et al. Patient Educ Couns. 2008;72(3): 411–417.
  3. Bailey RA et al. BMC Research Notes. 2014;7:415.
  4. International Diabetes Federation. IDF Global Guideline for Managing Older People with Type 2 Diabetes. https://www.idf.org/our-activities/advocacy-awareness/resources-and-tools/78:global-guideline-for-managing-older-people-with-type-2-diabetes.html. Last accessed 29/01/2018.
  5. Iglay K et al. Curr Med Res Opin. 2016;32:1243–1252.
  6. Centre for Disease Control and Prevention. Diabetes Data & Trends. Available at: http://www.cdc.gov/diabetes/statistics/hypoglycemia/fig5byage.html. Accessed January 2018.
  7. JANUVIA Summary of Product Characteristics.
  8. Barzilai N et al. Curr Med Res Opin. 2011;27:1049–1058.
  9. Green JB et al. N Engl J Med. 2015;373(3):232–242.
  10. NICE Guideline 28. Type 2 diabetes in adult management. May 2017. Available at: https://www.nice.org.uk/guidance/ng28/resources. Last accessed 23/01/2018.
  11. Bethel MA et al. Diabetes Care. 2017;40(4):494–501.
  12. Cornel JH et al. Diabetes Care. 2016;39(12):2304–2310.
  13. Krobot KJ et al. Curr Med Res Opin. 2012;28(8):1281-7.
  14. Nauck MA et al. Diabetes Obesity and Metabolism. 2007;9(2):194-205.

Supporting documentation

100 mg
Prescribing Information | Summary of Product Characteristics | Patient Information Leaflet

50 mg
Prescribing Information | Summary of Product Characteristics | Patient Information Leaflet

25 mg
Prescribing Information | Summary of Product Characteristics | Patient Information Leaflet

DIAB-1247350-0026 | Date of Preparation: March 2018